15,555 Shares in ResMed Inc. (NYSE:RMD) Acquired by Jericho Financial LLP

Jericho Financial LLP purchased a new stake in ResMed Inc. (NYSE:RMD - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 15,555 shares of the medical equipment provider's stock, valued at approximately $3,557,000. ResMed makes up about 2.6% of Jericho Financial LLP's investment portfolio, making the stock its 20th biggest holding.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Cetera Investment Advisers raised its holdings in shares of ResMed by 26.8% during the 2nd quarter. Cetera Investment Advisers now owns 9,721 shares of the medical equipment provider's stock worth $1,861,000 after buying an additional 2,053 shares in the last quarter. Sanctuary Advisors LLC bought a new position in shares of ResMed in the second quarter worth about $1,162,000. Czech National Bank grew its holdings in shares of ResMed by 6.9% during the 3rd quarter. Czech National Bank now owns 29,931 shares of the medical equipment provider's stock valued at $7,307,000 after purchasing an additional 1,936 shares during the last quarter. GAMMA Investing LLC increased its position in ResMed by 88.9% during the 3rd quarter. GAMMA Investing LLC now owns 2,501 shares of the medical equipment provider's stock worth $611,000 after purchasing an additional 1,177 shares in the last quarter. Finally, Miracle Mile Advisors LLC bought a new position in ResMed in the 3rd quarter valued at approximately $205,000. Institutional investors own 54.98% of the company's stock.

ResMed Stock Down 0.1 %

NYSE RMD traded down $0.34 on Friday, hitting $236.84. 830,561 shares of the company were exchanged, compared to its average volume of 1,059,213. ResMed Inc. has a 12 month low of $170.56 and a 12 month high of $263.05. The company has a current ratio of 3.33, a quick ratio of 2.29 and a debt-to-equity ratio of 0.13. The company has a market cap of $34.78 billion, a PE ratio of 27.96, a PEG ratio of 1.57 and a beta of 0.70. The stock has a fifty day moving average of $239.18 and a 200-day moving average of $237.39.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. As a group, analysts forecast that ResMed Inc. will post 9.44 earnings per share for the current year.

ResMed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date is Thursday, February 13th. ResMed's payout ratio is 25.03%.

Wall Street Analyst Weigh In

RMD has been the subject of several research analyst reports. Robert W. Baird upped their price target on shares of ResMed from $280.00 to $283.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. The Goldman Sachs Group started coverage on ResMed in a report on Thursday, January 16th. They issued a "buy" rating for the company. StockNews.com raised ResMed from a "hold" rating to a "buy" rating in a research note on Tuesday, October 15th. JPMorgan Chase & Co. raised their price objective on shares of ResMed from $270.00 to $286.00 and gave the company an "overweight" rating in a report on Friday, January 31st. Finally, UBS Group raised shares of ResMed from a "hold" rating to a "strong-buy" rating in a report on Friday, January 31st. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, ResMed has a consensus rating of "Moderate Buy" and an average target price of $244.73.

Insider Buying and Selling

In other news, insider Justin Leong sold 6,160 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $243.09, for a total transaction of $1,497,434.40. Following the completion of the transaction, the insider now directly owns 21,718 shares of the company's stock, valued at $5,279,428.62. This represents a 22.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Witte Jan De sold 796 shares of the company's stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the completion of the transaction, the director now owns 6,723 shares in the company, valued at approximately $1,672,749.63. The trade was a 10.59 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,094 shares of company stock worth $2,704,941. 0.71% of the stock is owned by company insiders.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.